Dishman Carbogen Amcis Ltd Stock Falls to 52-Week Low of Rs.175.4

Stock Performance and Market Context

On 25 Feb 2026, Dishman Carbogen Amcis Ltd recorded an intraday low of Rs.175.4, representing a 2.28% drop on the day and a 2.23% decline in the closing price. This marks the fifth consecutive day of losses, during which the stock has fallen by 11.41%. The stock’s current price is substantially below its 52-week high of Rs.321.15, indicating a depreciation of approximately 45.4% over the past year.

In comparison, the Sensex opened higher at 82,530.12 points, gaining 304.20 points (0.37%) but was trading marginally lower at 82,241.56 points (0.02%) during the same period. The Sensex remains 4.76% below its own 52-week high of 86,159.02 points. While mega-cap stocks are leading the market, Dishman Carbogen Amcis Ltd’s performance contrasts sharply with the broader market trend.

The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. Additionally, the stock underperformed its Pharmaceuticals & Biotechnology sector by 3.55% on the day, further highlighting its relative weakness.

Financial Metrics and Fundamental Assessment

Dishman Carbogen Amcis Ltd’s financial indicators reveal several areas of concern. The company’s long-term fundamental strength remains weak, with an average Return on Capital Employed (ROCE) of just 0.97%. This low ROCE suggests limited efficiency in generating returns from its capital base.

Net sales have grown at a modest annual rate of 8.10% over the last five years, which is below the growth rates typically expected in the Pharmaceuticals & Biotechnology sector. The company’s ability to service its debt is also constrained, with a high Debt to EBITDA ratio of 4.96 times, indicating significant leverage and potential pressure on cash flows.

Quarterly financials further underscore the challenges faced by the company. The Profit After Tax (PAT) stood at a negative Rs.12.97 crores, reflecting a steep decline of 403.0%. Operating profit to interest coverage ratio is at a low 2.47 times, signalling limited buffer to meet interest obligations. Quarterly PBDIT is also at a low Rs.113.11 crores, indicating subdued operating profitability.

Investor Participation and Market Sentiment

Institutional investors have reduced their holdings by 0.51% over the previous quarter, now collectively holding 8.93% of the company’s shares. This decline in institutional participation may reflect a reassessment of the company’s fundamentals by investors with greater analytical resources.

Over the past year, Dishman Carbogen Amcis Ltd has generated a negative return of 17.80%, significantly underperforming the Sensex, which posted a positive return of 10.24% during the same period. The stock has also lagged behind the BSE500 index over the last three years, one year, and three months, indicating persistent underperformance relative to broader market benchmarks.

Valuation and Relative Positioning

Despite the challenges, the company’s valuation metrics suggest a very attractive entry point from a purely valuation perspective. The ROCE of 3.2 and an Enterprise Value to Capital Employed ratio of 0.6 indicate that the stock is trading at a discount compared to its peers’ historical averages. The Price/Earnings to Growth (PEG) ratio stands at a low 0.1, reflecting the market’s subdued expectations for growth relative to earnings.

Profitability has shown some improvement, with profits rising by 233.1% over the past year, although this has not translated into positive returns for shareholders. The disconnect between profit growth and share price performance may be attributed to concerns over leverage, cash flow adequacy, and overall financial stability.

Summary of Key Metrics

Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 17.0 and a Mojo Grade of Strong Sell, upgraded from Sell on 12 Jan 2026. The company’s market capitalisation grade is 3, reflecting its mid-tier market cap status within the Pharmaceuticals & Biotechnology sector.

The stock’s recent performance, combined with its financial ratios and institutional investor behaviour, paints a picture of a company facing multiple headwinds. While valuation metrics indicate potential value, the prevailing market sentiment and fundamental indicators have contributed to the stock’s decline to its 52-week low.

Market and Sector Comparison

Within the Pharmaceuticals & Biotechnology sector, Dishman Carbogen Amcis Ltd’s underperformance is notable. The sector has generally maintained steadier valuations and returns, supported by stronger fundamentals among peers. The stock’s relative weakness is underscored by its consistent trading below all major moving averages and its lagging returns compared to sector benchmarks.

Meanwhile, the broader market, led by mega-cap stocks, has shown resilience with the Sensex maintaining proximity to its 52-week high. This divergence highlights the stock-specific challenges faced by Dishman Carbogen Amcis Ltd in an otherwise stable market environment.

Conclusion

Dishman Carbogen Amcis Ltd’s fall to Rs.175.4, its lowest level in 52 weeks, reflects a combination of subdued financial performance, high leverage, and reduced institutional interest. The stock’s persistent underperformance relative to the Sensex and its sector peers underscores the challenges it faces. While valuation metrics suggest the stock is trading at a discount, the prevailing market conditions and financial indicators have contributed to the current downtrend.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →